Payment overview · 2025
General Payments
$836.24
38 reported records · 17 companies
Healthcare provider profile · identity verified
Boyde J Harrison, MD
Allopathic & Osteopathic Physicians|Family Medicine · HALEYVILLE, AL · NPI 1619908571
Verified facts
What the public records show
CMS Open Payments records show Boyde J Harrison, MD received $836.24 in general payments during 2025 across 38 reported records.
AstraZeneca Pharmaceuticals LP accounted for 19.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 20 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Mounjaro, Rexulti, Sublocade, Trelegy Ellipta, Vraylar, Xifaxan.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 185 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Vraylar by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BEVESPI AEROSPHERE as an associated drug or biological on 763 records involving 473 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Bevespi Aerosphere by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 503 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Symbicort by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 219 claims for Trelegy Ellipta by this doctor in 2024.
Indivior Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SUBLOCADE as an associated drug or biological on 22829 records involving 8874 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Sublocade by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 324 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 66 claims for Trulicity by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 360 claims for Entresto by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NUEDEXTA as an associated drug or biological on 393 records involving 285 distinct recipient NPIs. Public Medicare Part D data also shows 51 claims for Nuedexta by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rexulti by this doctor in 2024.
Otsuka Pharmaceutical Development & Commercialization, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 1463 records involving 1088 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Rexulti by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 1460 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Paxlovid by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 39 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 86 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.54 | 19.4% | 8 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $125.00 | 14.9% | 1 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $69.49 | 8.3% | 4 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $58.69 | 7.0% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $58.18 | 7.0% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $50.64 | 6.1% | 3 | 2025 |
| Braeburn Inc. | Unresolved — no canonical attribution shown | $42.68 | 5.1% | 3 | 2025 |
| Teva Pharmaceuticals USA, Inc. | Unresolved — no canonical attribution shown | $38.45 | 4.6% | 2 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $37.46 | 4.5% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $36.82 | 4.4% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $34.10 | 4.1% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $25.82 | 3.1% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $22.27 | 2.7% | 1 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $22.23 | 2.7% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $20.35 | 2.4% | 1 | 2025 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | Unresolved — no canonical attribution shown | $17.49 | 2.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $14.03 | 1.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $836.24 | 38 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $141.27 | 7 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $125.00 | 1 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $69.49 | 4 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $58.69 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $58.18 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $50.64 | 3 | 2025 |
Source payment records
|
|||||
| BRIXADI Normalized: brixadi |
Drug | Braeburn Inc. | $42.68 | 3 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $37.95 | 2 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc., Otsuka Pharmaceutical Development & Commercialization, Inc. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $36.82 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $34.10 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $25.82 | 1 | 2025 |
Source payment records
|
|||||
| AUSTEDO XR Normalized: austedo xr |
Drug | Teva Pharmaceuticals USA, Inc. | $22.79 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| Leqembi Normalized: leqembi |
Drug | Eisai Inc. | $22.23 | 1 | 2025 |
Source payment records
|
|||||
| UZEDY Normalized: uzedy |
Drug | Teva Pharmaceuticals USA, Inc. | $15.66 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 1460 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 503 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 52 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SUBLOCADE sublocade |
2025 | Sublocade | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 219 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 86 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
185 | 40 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BEVESPI AEROSPHERE open payments reported associated product |
CMS Open Payments — General Payments 763 supporting records · 473 recipient NPIs · example record 1206131384 |
Bevespi Aerosphere · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
503 | 58 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
26 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
219 | 46 |
| Indivior Inc. Exact reporting entity; no affiliate inference |
2025 | SUBLOCADE open payments reported associated product |
CMS Open Payments — General Payments 22829 supporting records · 8874 recipient NPIs · example record 1240470773 |
Sublocade · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
324 | 42 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
66 | 16 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
360 | 36 |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | NUEDEXTA open payments reported associated product |
CMS Open Payments — General Payments 393 supporting records · 285 recipient NPIs · example record 1227268901 |
Nuedexta · 2024 Exact normalized brand match · 1 Part D row |
51 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| Otsuka Pharmaceutical Development & Commercialization, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 1463 supporting records · 1088 recipient NPIs · example record 1225319865 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
52 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
25 | 25 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
1460 | 122 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
16 | 16 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
39 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
86 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Levothyroxine Sodium | Levothyroxine Sodium | 1682 | 201 |
| Atorvastatin Calcium | Atorvastatin Calcium | 1522 | 286 |
| Eliquis | Apixaban | 1460 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 1379 | 252 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 1369 | 297 |
| Pantoprazole Sodium | Pantoprazole Sodium | 1344 | 220 |
| Gabapentin | Gabapentin | 1178 | 230 |
| Furosemide | Furosemide | 1133 | 197 |
| Trazodone Hcl | Trazodone Hcl | 1091 | 199 |
| Lisinopril | Lisinopril | 1026 | 198 |
| Mirtazapine | Mirtazapine | 986 | 164 |
| Duloxetine Hcl | Duloxetine Hcl | 935 | 118 |
| Potassium Chloride | Potassium Chloride | 892 | 147 |
| Buspirone Hcl | Buspirone Hcl | 808 | 123 |
| Famotidine | Famotidine | 792 | 114 |
| Tamsulosin Hcl | Tamsulosin Hcl | 688 | 114 |
| Escitalopram Oxalate | Escitalopram Oxalate | 668 | 133 |
| Buprenorphine-Naloxone | Buprenorphine Hcl/Naloxone Hcl | 643 | 134 |
| Metoprolol Succinate | Metoprolol Succinate | 635 | 112 |
| Omeprazole | Omeprazole | 608 | 127 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 601 | 146 |
| Metoprolol Tartrate | Metoprolol Tartrate | 513 | 80 |
| Farxiga | Dapagliflozin Propanediol | 503 | 58 |
| Lorazepam | Lorazepam | 493 | 102 |
| Metformin Hcl | Metformin Hcl | 460 | 94 |
| Donepezil Hcl | Donepezil Hcl | 452 | 70 |
| Sertraline Hcl | Sertraline Hcl | 448 | 80 |
| Memantine Hcl | Memantine Hcl | 445 | 66 |
| Carvedilol | Carvedilol | 441 | 74 |
| Quetiapine Fumarate | Quetiapine Fumarate | 437 | 88 |
| Clopidogrel | Clopidogrel Bisulfate | 419 | 67 |
| Clonazepam | Clonazepam | 417 | 76 |
| Losartan Potassium | Losartan Potassium | 377 | 70 |
| Ondansetron Hcl | Ondansetron Hcl | 370 | 104 |
| Ropinirole Hcl | Ropinirole Hcl | 369 | 51 |
| Montelukast Sodium | Montelukast Sodium | 363 | 60 |
| Entresto | Sacubitril/Valsartan | 360 | 36 |
| Risperidone | Risperidone | 353 | 46 |
| Tizanidine Hcl | Tizanidine Hcl | 349 | 70 |
| Jardiance | Empagliflozin | 324 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 311 | 63 |
| Levetiracetam | Levetiracetam | 302 | 44 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 294 | 45 |
| Pregabalin | Pregabalin | 293 | 57 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 292 | 64 |
| Citalopram Hbr | Citalopram Hydrobromide | 288 | 53 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 282 | 98 |
| Celecoxib | Celecoxib | 275 | 55 |
| Tradjenta | Linagliptin | 260 | 18 |
| Bupropion Xl | Bupropion Hcl | 257 | 49 |
| Divalproex Sodium | Divalproex Sodium | 257 | 49 |
| Meloxicam | Meloxicam | 246 | 49 |
| Tramadol Hcl | Tramadol Hcl | 232 | 68 |
| Spironolactone | Spironolactone | 224 | 37 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 219 | 32 |
| Simvastatin | Simvastatin | 219 | 58 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 219 | 46 |
| Hydralazine Hcl | Hydralazine Hcl | 216 | 52 |
| Januvia | Sitagliptin Phosphate | 214 | 33 |
| Sucralfate | Sucralfate | 214 | 24 |
| Allopurinol | Allopurinol | 203 | 36 |
| Myrbetriq | Mirabegron | 202 | 18 |
| Gemtesa | Vibegron | 195 | 15 |
| Diazepam | Diazepam | 193 | 42 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 190 | 60 |
| Linzess | Linaclotide | 185 | 40 |
| Finasteride | Finasteride | 183 | 25 |
| Fluoxetine Hcl | Fluoxetine Hcl | 181 | 42 |
| Methocarbamol | Methocarbamol | 180 | 46 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 179 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 176 | 44 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 175 | 45 |
| Ondansetron Odt | Ondansetron | 172 | 60 |
| Lactulose | Lactulose | 168 | 34 |
| Oxycodone Hcl | Oxycodone Hcl | 161 | 38 |
| Hydrochlorothiazide | Hydrochlorothiazide | 153 | 43 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 152 | 27 |
| Alprazolam | Alprazolam | 151 | 22 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 151 | 51 |
| Fluticasone Propionate | Fluticasone Propionate | 143 | 35 |
| Xarelto | Rivaroxaban | 143 | 15 |
| Amiodarone Hcl | Amiodarone Hcl | 141 | 26 |
| Diclofenac Sodium | Diclofenac Sodium | 138 | 52 |
| Olanzapine | Olanzapine | 138 | 30 |
| Clonidine Hcl | Clonidine Hcl | 134 | 42 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 132 | 32 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 126 | 27 |
| Ceftriaxone | Ceftriaxone Sodium | 125 | 70 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 123 | 23 |
| Benazepril Hcl | Benazepril Hcl | 119 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 118 | 21 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 115 | 22 |
| Fenofibrate | Fenofibrate Nanocrystallized | 113 | 18 |
| Topiramate | Topiramate | 113 | 20 |
| Alendronate Sodium | Alendronate Sodium | 111 | 25 |
| Ozempic | Semaglutide | 107 | 23 |
| Fenofibrate | Fenofibrate | 106 | 30 |
| Metoclopramide Hcl | Metoclopramide Hcl | 106 | 19 |
| Oxcarbazepine | Oxcarbazepine | 104 | 14 |
| Aripiprazole | Aripiprazole | 101 | 18 |
| Ranolazine Er | Ranolazine | 101 | 12 |
| Labetalol Hcl | Labetalol Hcl | 99 | 39 |
| Latanoprost | Latanoprost | 98 | 17 |
| Prednisone | Prednisone | 98 | 46 |
| Cephalexin | Cephalexin | 97 | 72 |
| Fluconazole | Fluconazole | 95 | 59 |
| Metformin Hcl Er | Metformin Hcl | 95 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 94 | 17 |
| Diltiazem Hcl | Diltiazem Hcl | 94 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 92 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 90 | 17 |
| Nystatin | Nystatin | 90 | 41 |
| Ezetimibe | Ezetimibe | 89 | 22 |
| Dapagliflozin | Dapagliflozin Propanediol | 88 | 28 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 88 | 20 |
| Baclofen | Baclofen | 87 | suppressed |
| Xifaxan | Rifaximin | 86 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 85 | 17 |
| Lidocaine Hcl | Lidocaine Hcl | 81 | 53 |
| Primidone | Primidone | 81 | 15 |
| Humalog Kwikpen U-100 | Insulin Lispro | 79 | suppressed |
| Glimepiride | Glimepiride | 78 | 20 |
| Ingrezza | Valbenazine Tosylate | 78 | suppressed |
| Valsartan | Valsartan | 78 | 20 |
| Estradiol | Estradiol | 75 | 16 |
| Levofloxacin | Levofloxacin | 75 | 68 |
| Ibuprofen | Ibuprofen | 74 | 21 |
| Invokana | Canagliflozin | 74 | suppressed |
| Levemir | Insulin Detemir | 71 | suppressed |
| Haloperidol | Haloperidol | 67 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 66 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 66 | suppressed |
| Trulicity | Dulaglutide | 66 | 16 |
| Warfarin Sodium | Warfarin Sodium | 66 | suppressed |
| Amlodipine-Valsartan | Amlodipine Besylate/Valsartan | 65 | 20 |
| Lamotrigine | Lamotrigine | 65 | 12 |
| Lovastatin | Lovastatin | 65 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 65 | suppressed |
| Risperidone Odt | Risperidone | 64 | suppressed |
| Roflumilast | Roflumilast | 64 | suppressed |
| Lidocaine | Lidocaine | 63 | 13 |
| Atenolol | Atenolol | 62 | 14 |
| Irbesartan | Irbesartan | 62 | 15 |
| Midodrine Hcl | Midodrine Hcl | 61 | 14 |
| Digoxin | Digoxin | 59 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 59 | 35 |
| Oxybutynin Chloride | Oxybutynin Chloride | 59 | 12 |
| Prazosin Hcl | Prazosin Hcl | 58 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 56 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 56 | suppressed |
| Valproic Acid | Valproic Acid (As Sodium Salt) | 56 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 55 | 11 |
| Lacosamide | Lacosamide | 53 | suppressed |
| Lansoprazole | Lansoprazole | 53 | 11 |
| Budesonide | Budesonide | 52 | suppressed |
| Insulin Lispro | Insulin Lispro | 52 | 14 |
| Rexulti | Brexpiprazole | 52 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 51 | 21 |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 51 | suppressed |
| Rivastigmine | Rivastigmine | 51 | suppressed |
| Suboxone | Buprenorphine Hcl/Naloxone Hcl | 49 | 16 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 48 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 48 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 47 | suppressed |
| Novolog | Insulin Aspart | 47 | 15 |
| Ondansetron Hcl | Ondansetron Hcl/Pf | 47 | 26 |
| Carbamazepine | Carbamazepine | 45 | suppressed |
| Fentanyl | Fentanyl | 45 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 45 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 45 | 27 |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 44 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 43 | 22 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 43 | 36 |
| Cefdinir | Cefdinir | 42 | 32 |
| Humalog | Insulin Lispro | 42 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 41 | 12 |
| Glipizide | Glipizide | 41 | suppressed |
| Metolazone | Metolazone | 41 | suppressed |
| Ketoconazole | Ketoconazole | 40 | 15 |
| Bydureon Bcise | Exenatide Microspheres | 39 | suppressed |
| Doxepin Hcl | Doxepin Hcl | 39 | suppressed |
| Trulance | Plecanatide | 39 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 38 | 12 |
| Vascepa | Icosapent Ethyl | 38 | suppressed |
| Vraylar | Cariprazine Hcl | 38 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 37 | 29 |
| Enulose | Lactulose | 37 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 37 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 37 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 37 | 11 |
| Diltiazem 24hr Er | Diltiazem Hcl | 36 | suppressed |
| Verapamil Er | Verapamil Hcl | 36 | suppressed |
| Lubiprostone | Lubiprostone | 35 | suppressed |
| Chlorthalidone | Chlorthalidone | 34 | suppressed |
| Cilostazol | Cilostazol | 34 | suppressed |
| Mupirocin | Mupirocin | 33 | 23 |
| Nuplazid | Pimavanserin Tartrate | 33 | suppressed |
| Ramipril | Ramipril | 33 | suppressed |
| Sublocade | Buprenorphine | 33 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 29 |
| Eszopiclone | Eszopiclone | 32 | suppressed |
| Movantik | Naloxegol Oxalate | 32 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 32 | suppressed |
| Santyl | Collagenase Clostridium Hist. | 32 | 19 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 31 | 14 |
| Nitroglycerin | Nitroglycerin | 31 | 27 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 31 | 28 |
| Terazosin Hcl | Terazosin Hcl | 31 | suppressed |
| Bumetanide | Bumetanide | 30 | suppressed |
| Methenamine Hippurate | Methenamine Hippurate | 30 | suppressed |
| Sotalol | Sotalol Hcl | 30 | suppressed |
| Timolol Maleate | Timolol Maleate | 30 | suppressed |
| Azithromycin | Azithromycin | 29 | 15 |
| Buprenorphine | Buprenorphine | 29 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 29 | suppressed |
| Temazepam | Temazepam | 29 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 28 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 28 | suppressed |
| Gemfibrozil | Gemfibrozil | 28 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 28 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 28 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 28 | suppressed |
| Scopolamine | Scopolamine | 28 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 27 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 27 | suppressed |
| Isosorbide Mononitrate | Isosorbide Mononitrate | 26 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 26 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 26 | suppressed |
| Paliperidone Er | Paliperidone | 26 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 26 | suppressed |
| Zubsolv | Buprenorphine Hcl/Naloxone Hcl | 26 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 25 | 25 |
| Divalproex Sodium Er | Divalproex Sodium | 25 | suppressed |
| Haloperidol Decanoate | Haloperidol Decanoate | 25 | suppressed |
| Medroxyprogesterone Acetate | Medroxyprogesterone Acetate | 25 | suppressed |
| Metronidazole | Metronidazole | 25 | 12 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 25 | suppressed |
| Acetazolamide | Acetazolamide | 24 | suppressed |
| Brimonidine Tartrate | Brimonidine Tartrate | 24 | suppressed |
| Gentamicin Sulfate | Gentamicin Sulfate | 24 | 16 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | 11 |
| Carbidopa-Levodopa-Entacapone | Carbidopa/Levodopa/Entacapone | 23 | suppressed |
| Clonidine | Clonidine | 23 | suppressed |
| Glipizide Er | Glipizide | 23 | suppressed |
| Letrozole | Letrozole | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Nystop | Nystatin | 23 | 15 |
| Unifine Safecontrol Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Zonisamide | Zonisamide | 23 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 22 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 22 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 22 | suppressed |
| Nifedipine Er | Nifedipine | 21 | suppressed |
| Phenobarbital | Phenobarbital | 21 | suppressed |
| Torsemide | Torsemide | 21 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 20 | suppressed |
| Brilinta | Ticagrelor | 20 | suppressed |
| Cyclosporine | Cyclosporine | 20 | suppressed |
| Dulera | Mometasone/Formoterol | 20 | suppressed |
| Glucagon Emergency Kit | Glucagon | 20 | 12 |
| Raloxifene Hcl | Raloxifene Hcl | 20 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 20 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Benazepril-Hydrochlorothiazide | Benazepril/Hydrochlorothiazide | 19 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 19 | suppressed |
| Erythromycin | Erythromycin Base | 19 | 11 |
| Fluticasone-Vilanterol | Fluticasone/Vilanterol | 19 | suppressed |
| Prilosec | Omeprazole Magnesium | 19 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 19 | suppressed |
| Xtampza Er | Oxycodone Myristate | 19 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 18 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 18 | suppressed |
| Nucynta Er | Tapentadol Hcl | 18 | suppressed |
| Pitavastatin Calcium | Pitavastatin Calcium | 18 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 18 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Belsomra | Suvorexant | 17 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 17 | suppressed |
| Lidocaine Hcl Viscous | Lidocaine Hcl | 17 | suppressed |
| Mirabegron Er | Mirabegron | 17 | suppressed |
| Cyproheptadine Hcl | Cyproheptadine Hcl | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 16 | suppressed |
| Sevelamer Carbonate | Sevelamer Carbonate | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 16 | suppressed |
| Amantadine | Amantadine Hcl | 15 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 15 | suppressed |
| Colchicine | Colchicine | 15 | 11 |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 15 | suppressed |
| Lisdexamfetamine Dimesylate | Lisdexamfetamine Dimesylate | 15 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 15 | suppressed |
| Novofine Autocover | Pen Needle, Diabetic, Safety | 15 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 14 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Hydroxyurea | Hydroxyurea | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Mounjaro | Tirzepatide | 14 | suppressed |
| Nystatin-Triamcinolone | Nystatin/Triamcinolone Acet | 14 | 12 |
| Restasis | Cyclosporine | 14 | suppressed |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 14 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 12 | suppressed |
| Bevespi Aerosphere | Glycopyrrolate/Formoterol Fum | 12 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 12 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 12 | suppressed |
| Clozapine | Clozapine | 12 | suppressed |
| Ezetimibe-Simvastatin | Ezetimibe/Simvastatin | 12 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 12 | suppressed |
| Methotrexate | Methotrexate Sodium | 12 | suppressed |
| Olanzapine Odt | Olanzapine | 12 | suppressed |
| Phenytoin | Phenytoin | 12 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 12 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 11 | suppressed |
| Belbuca | Buprenorphine Hcl | 11 | suppressed |
| Briviact | Brivaracetam | 11 | suppressed |
| Entacapone | Entacapone | 11 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 11 | suppressed |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 11 | suppressed |
| Lithium Carbonate Er | Lithium Carbonate | 11 | suppressed |
| Paricalcitol | Paricalcitol | 11 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 11 | suppressed |
| Victoza 3-Pak | Liraglutide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $836.24 · 38 records | AstraZeneca Pharmaceuticals LP | AREXVY, AUSTEDO XR, BREZTRI, BRIXADI, ELIQUIS, FARXIGA, Korlym, LEQVIO, Leqembi, MOUNJARO, NURTEC ODT, OTEZLA, REPATHA, REXULTI, SUBLOCADE, TRELEGY ELLIPTA, UZEDY, VERQUVO, VRAYLAR, XIFAXAN | 21 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error